INFLAMMATORY BIOMARKERS FOR MONITORING DEPRESSIVE DISORDERS
Materials and Methods related to developing a unipolar depression (MDD) disease score in a subject using a multi-parameter system to measure a plurality of parameters, and an algorithm to calculate a score.
1 . A method for characterizing depression in a subject, comprising
(a) providing a numerical value for a plurality of analytes relevant to depression;
(b) individually weighting each numerical value in a manner specific to each analyte to obtain a weighted value for each analyte;
(c) determining a result value based on an equation that includes each weighted value;
(d) determining the difference between said result value and a control result value, wherein the control result value was determined in a manner comparable to that of the result value, with the proviso that each control numerical value corresponds to the level of said analyte in a biological sample from a normal subject; and
(e) if said difference is greater than a threshold indicative of depression, classifying said subject as having depression, or, if said difference is not greater than said threshold, classifying said subject as not having depression.
2 . The method of claim 1 , wherein said depression is associated with major depressive disorder (MDD).
3 . The method of claim 1 , wherein said analytes are selected from the group consisting of interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-10 (IL-10), interleukin-13 (IL-13), interleukin-15 (IL-15), interleukin-18 (IL-18), alpha-2-macroglobin (A2M), and beta-2 macroglobulin (B2M).
4 . The method of claim 1 , wherein said analytes are selected from the group consisting of cortisol, IL-1, IL-6, IL-7, IL-10, IL-13, IL-15, IL-18, and A2M.
5 - 9 . (canceled)
10 . The method of claim 4 , wherein said analytes further comprise one or more of neuropeptide Y, ACTH, arginine vasopressin, and brain-derived neurotrophic factor.
11 . The method of claim 4 , wherein said analytes further comprise platelet associated serotonin.
12 . The method of any claim 4 , wherein said analytes further comprise serum or plasma levels of one or more of fatty acid binding protein, alpha-1 antitrypsin, factor VII, epidermal growth factor, glutathione S-transferase, RANTES, plasminogen activator inhibitor type 1, and tissue inhibitor of metalloproteinase type 1.
13 . The method of claim 1 , wherein said numerical values are analyte levels in a biological sample from said subject.
14 . The method of claim 13 , wherein said biological sample is whole blood, serum, plasma, urine, or cerebrospinal fluid.
15 - 18 . (canceled)
19 . The method of claim 1 , wherein said result value is statistically different from said control result value at p<0.05.
20 . (canceled)
21 . The method of claim 1 , wherein said subject is a human.
22 . The method of claim 1 , further comprising providing a numerical value for one or more parameters selected from the group consisting of magnetic resonance imaging, magnetic resonance spectroscopy, computerized tomography scanning, and body mass index.
23 . The method of claim 1 , further comprising providing a biological sample from said subject.
24 . The method of claim 1 , further comprising measuring the level of each of said plurality of analytes to obtain said numerical values.
25 . A method for monitoring treatment for MDD, comprising:
(a) providing a numerical value for a plurality of parameters in a subject diagnosed as having MDD, said parameters being relevant to MDD;
(b) using an algorithm comprising said numerical values to calculate an MDD score;
(c) repeating steps (a) and (b) after a period of time during which said subject receives treatment for MDD, to obtain a post-treatment MDD score;
(d) comparing the post-treatment MDD score from step (c) to the score in step (b) and to a MDD score for normal subjects, and classifying said treatment as being effective if the score from step (c) is closer than the score from step (b) to the MDD score for normal subjects.
26 . The method of claim 25 , wherein step (b) comprises individually weighting each numerical value in a manner specific to each parameter to obtain a weighted value for each parameter, and calculating a result value based on an equation that includes each weighted value.
27 . The method of claim 25 , wherein said parameters comprise analytes selected from the group consisting of IL-1, IL-6, IL-7, IL-10, IL-13, IL-15, IL-18, A2M, and B2M.
28 . The method of claim 25 , wherein said period of time ranges from weeks to months after the onset of said treatment.
29 . The process of claim 25 , wherein a subset of said numerical values are provided for time points prior to and after initiation of said treatment.
30 . The method of claim 25 , wherein said parameters comprise measurements derived from magnetic resonance imaging, magnetic resonance spectroscopy, or computerized tomography scans.
31 . The method of claim 25 , wherein said numerical values are biomarker levels in a biological sample from said subject.
32 . The method of claim 31 , wherein said biological sample is serum, plasma, urine, or cerebrospinal fluid.
33 - 35 . (canceled)
36 . The method of claim 25 , further comprising providing a biological sample from said subject.
37 . The method of claim 25 , further comprising measuring the levels of said plurality of parameters to obtain said numerical values.
38 . A computer-implemented method for diagnosing MDD, comprising:
providing a biomarker library database that includes selected biomarker parameters that are relevant to MDD, sets of combinations of the biomarkers, and coefficients the sets of combinations based on clinical data obtained from patients with MDD; and
using a computer processor to apply a set of combinations of the biomarkers and associated coefficients to measured values of the biomarkers in the set obtained from a patient based on an algorithm to produce an MDD score for diagnosing whether the patient has MDD.